dataplor Launches Global Mobility Product, Expanding Foot Traffic Insights to Major Markets Worldwide
20.5.2025 12:00:00 CEST | Business Wire | Press Release
dataplor, a leading provider of global location intelligence, has announced the launch of its global mobility product, delivering high-quality, privacy-compliant foot traffic data across international markets. Designed to meet growing demand from multinational businesses, the product offers monthly refreshed insights into consumer movement patterns across cities, regions, and points of interest (POIs), especially in previously under-mapped markets. It’s one of the only global solutions built to deliver this depth of mobility data while maintaining General Data Protection Regulation (GDPR) compliance and end-user privacy.
To showcase the power of its new global dataset, dataplor is releasing the Global Foot Traffic Trends: What the World's Most Visited Places Reveal About Tourism’s Return report, which analyzes foot traffic at the world’s most visited tourist attractions. The report highlights how mobility data reveals meaningful insights about international travel patterns and regional consumer behavior from Tokyo Disneyland to the Great Pyramid at Giza.
“Global companies need the same level of location intelligence abroad that they’ve come to expect in the U.S.,” said Geoff Michener, CEO of dataplor. “With our international mobility product, businesses can now access comprehensive, GDPR-compliant foot traffic data across both developed and emerging markets, helping them make smarter decisions about where to invest, expand, and serve customers.”
New Applications Across Regions and Industries
With access to reliable mobility data across international markets, dataplor’s global offering empowers organizations to:
- Uncover new revenue opportunities by identifying untapped sales channels, benchmarking competitor foot traffic, and forecasting demand to inform international expansion and investment decisions.
- Enhance tourism and hospitality strategies by understanding how international visitors move through major cities, landmarks, and cultural destinations.
- Support smart city and infrastructure development through real-world mobility data that enables governments and urban planners to optimize transit systems, pedestrian flows, and city design.
As with its North American offering, dataplor ensures international mobility data is collected via anonymized signals mapped against its proprietary POI database. The result is a precision-focused, GDPR-compliant, ethically sourced dataset that respects user privacy while meeting the demands of modern global businesses.
For more information about the report and the global mobility product, read dataplor’s latest blog or visit www.dataplor.com.
About dataplor
dataplor is a leading provider of point-of-interest (POI) and mobility data that helps global enterprises grow abroad by mapping tough-to-reach markets with a privacy-first approach. As the majority of international location data is often inaccurate and quickly outdated, dataplor goes several steps beyond the industry standard, helping the world’s largest companies across technology, mapping, search, third-party logistics, consumer packaged goods (CPG), telecom, investing, real estate, and finance understand location intelligence about any commercial or physical location in real-time, fueling their expansion abroad.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520519636/en/
Contacts
media@dataplor.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom